Clonal analyses define the relationships between chromosomal abnormalities and JAK2V617F in patients with Ph-negative myeloproliferative neoplasms*

Xiaoli Wang, Amanda LeBlanc, Steven Gruenstein, Mingjiang Xu, John Mascarenhas, Brenda Panzera, Nathaniel Wisch, Charles Parker, Judith D. Goldberg, Josef Prchal, Ronald Hoffman, Vesna Najfeld

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objective: JAK2V617F occurs in ∼93% of patients with polycythemia vera and ∼50% of patients with either primary myelofibrosis or essential thrombocythemia. Chromosomal abnormalities are detected in 50% of patients with primary myelofibrosis, 29% with polycythemia vera, and 8% to 10% with essential thrombocythemia. The relationship between the presence of such chromosomal abnormalities and the JAK2V617 allele burden, and the role that each of these genetic events play in the origins and progression of the myeloproliferative neoplasms (MPNs), remain unclear. Materials and Methods: Individual hematopoietic colonies were assayed in vitro from the CD34+ cells of six JAK2V617F-positive MPN patients with marker chromosomal abnormalities. Colonies were simultaneously analyzed for JAK2 genotype and chromosomal abnormalities. Results: Among the 248 colonies assayed from cultures containing 500 CD34+ cells, chromosomal abnormalities were detected in 5% of colonies with wild-type JAK2, 32% of JAK2V617F heterozygous colonies and 56% of JAK2V617F homozygous colonies. Overall, 92% of chromosomally abnormal colonies were also JAK2V617F homozygous. Although 54 colonies contained wild-type JAK2 exclusively, 4 of these colonies were characterized by chromosomal abnormalities. Conclusion: This study indicates that MPN hematopoietic progenitor cells do not necessarily always acquire genetic events in the same sequence. (Chromosomally abnormal progenitor cells are closely associated with JAK2V617F homozygosity; p = 0.0001.). Chromosomal abnormalities such as +8, +9 can occasionally precede acquisition of JAK2V617F. These findings support the existence of earlier genetic events that precede JAK2V617F or cytogenetic abnormalities in MPN hematopoietic progenitor cells.

Original languageEnglish (US)
Pages (from-to)1194-1200
Number of pages7
JournalExperimental Hematology
Volume37
Issue number10
DOIs
StatePublished - Oct 2009
Externally publishedYes

Fingerprint

Chromosome Aberrations
Essential Thrombocythemia
Neoplasms
Polycythemia Vera
Primary Myelofibrosis
Hematopoietic Stem Cells
Stem Cells
Alleles
Genotype

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Genetics
  • Molecular Biology
  • Hematology

Cite this

Clonal analyses define the relationships between chromosomal abnormalities and JAK2V617F in patients with Ph-negative myeloproliferative neoplasms*. / Wang, Xiaoli; LeBlanc, Amanda; Gruenstein, Steven; Xu, Mingjiang; Mascarenhas, John; Panzera, Brenda; Wisch, Nathaniel; Parker, Charles; Goldberg, Judith D.; Prchal, Josef; Hoffman, Ronald; Najfeld, Vesna.

In: Experimental Hematology, Vol. 37, No. 10, 10.2009, p. 1194-1200.

Research output: Contribution to journalArticle

Wang, X, LeBlanc, A, Gruenstein, S, Xu, M, Mascarenhas, J, Panzera, B, Wisch, N, Parker, C, Goldberg, JD, Prchal, J, Hoffman, R & Najfeld, V 2009, 'Clonal analyses define the relationships between chromosomal abnormalities and JAK2V617F in patients with Ph-negative myeloproliferative neoplasms*', Experimental Hematology, vol. 37, no. 10, pp. 1194-1200. https://doi.org/10.1016/j.exphem.2009.07.003
Wang, Xiaoli ; LeBlanc, Amanda ; Gruenstein, Steven ; Xu, Mingjiang ; Mascarenhas, John ; Panzera, Brenda ; Wisch, Nathaniel ; Parker, Charles ; Goldberg, Judith D. ; Prchal, Josef ; Hoffman, Ronald ; Najfeld, Vesna. / Clonal analyses define the relationships between chromosomal abnormalities and JAK2V617F in patients with Ph-negative myeloproliferative neoplasms*. In: Experimental Hematology. 2009 ; Vol. 37, No. 10. pp. 1194-1200.
@article{7425fc4165b64c629cd330e2b163ce37,
title = "Clonal analyses define the relationships between chromosomal abnormalities and JAK2V617F in patients with Ph-negative myeloproliferative neoplasms*",
abstract = "Objective: JAK2V617F occurs in ∼93{\%} of patients with polycythemia vera and ∼50{\%} of patients with either primary myelofibrosis or essential thrombocythemia. Chromosomal abnormalities are detected in 50{\%} of patients with primary myelofibrosis, 29{\%} with polycythemia vera, and 8{\%} to 10{\%} with essential thrombocythemia. The relationship between the presence of such chromosomal abnormalities and the JAK2V617 allele burden, and the role that each of these genetic events play in the origins and progression of the myeloproliferative neoplasms (MPNs), remain unclear. Materials and Methods: Individual hematopoietic colonies were assayed in vitro from the CD34+ cells of six JAK2V617F-positive MPN patients with marker chromosomal abnormalities. Colonies were simultaneously analyzed for JAK2 genotype and chromosomal abnormalities. Results: Among the 248 colonies assayed from cultures containing 500 CD34+ cells, chromosomal abnormalities were detected in 5{\%} of colonies with wild-type JAK2, 32{\%} of JAK2V617F heterozygous colonies and 56{\%} of JAK2V617F homozygous colonies. Overall, 92{\%} of chromosomally abnormal colonies were also JAK2V617F homozygous. Although 54 colonies contained wild-type JAK2 exclusively, 4 of these colonies were characterized by chromosomal abnormalities. Conclusion: This study indicates that MPN hematopoietic progenitor cells do not necessarily always acquire genetic events in the same sequence. (Chromosomally abnormal progenitor cells are closely associated with JAK2V617F homozygosity; p = 0.0001.). Chromosomal abnormalities such as +8, +9 can occasionally precede acquisition of JAK2V617F. These findings support the existence of earlier genetic events that precede JAK2V617F or cytogenetic abnormalities in MPN hematopoietic progenitor cells.",
author = "Xiaoli Wang and Amanda LeBlanc and Steven Gruenstein and Mingjiang Xu and John Mascarenhas and Brenda Panzera and Nathaniel Wisch and Charles Parker and Goldberg, {Judith D.} and Josef Prchal and Ronald Hoffman and Vesna Najfeld",
year = "2009",
month = "10",
doi = "10.1016/j.exphem.2009.07.003",
language = "English (US)",
volume = "37",
pages = "1194--1200",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - Clonal analyses define the relationships between chromosomal abnormalities and JAK2V617F in patients with Ph-negative myeloproliferative neoplasms*

AU - Wang, Xiaoli

AU - LeBlanc, Amanda

AU - Gruenstein, Steven

AU - Xu, Mingjiang

AU - Mascarenhas, John

AU - Panzera, Brenda

AU - Wisch, Nathaniel

AU - Parker, Charles

AU - Goldberg, Judith D.

AU - Prchal, Josef

AU - Hoffman, Ronald

AU - Najfeld, Vesna

PY - 2009/10

Y1 - 2009/10

N2 - Objective: JAK2V617F occurs in ∼93% of patients with polycythemia vera and ∼50% of patients with either primary myelofibrosis or essential thrombocythemia. Chromosomal abnormalities are detected in 50% of patients with primary myelofibrosis, 29% with polycythemia vera, and 8% to 10% with essential thrombocythemia. The relationship between the presence of such chromosomal abnormalities and the JAK2V617 allele burden, and the role that each of these genetic events play in the origins and progression of the myeloproliferative neoplasms (MPNs), remain unclear. Materials and Methods: Individual hematopoietic colonies were assayed in vitro from the CD34+ cells of six JAK2V617F-positive MPN patients with marker chromosomal abnormalities. Colonies were simultaneously analyzed for JAK2 genotype and chromosomal abnormalities. Results: Among the 248 colonies assayed from cultures containing 500 CD34+ cells, chromosomal abnormalities were detected in 5% of colonies with wild-type JAK2, 32% of JAK2V617F heterozygous colonies and 56% of JAK2V617F homozygous colonies. Overall, 92% of chromosomally abnormal colonies were also JAK2V617F homozygous. Although 54 colonies contained wild-type JAK2 exclusively, 4 of these colonies were characterized by chromosomal abnormalities. Conclusion: This study indicates that MPN hematopoietic progenitor cells do not necessarily always acquire genetic events in the same sequence. (Chromosomally abnormal progenitor cells are closely associated with JAK2V617F homozygosity; p = 0.0001.). Chromosomal abnormalities such as +8, +9 can occasionally precede acquisition of JAK2V617F. These findings support the existence of earlier genetic events that precede JAK2V617F or cytogenetic abnormalities in MPN hematopoietic progenitor cells.

AB - Objective: JAK2V617F occurs in ∼93% of patients with polycythemia vera and ∼50% of patients with either primary myelofibrosis or essential thrombocythemia. Chromosomal abnormalities are detected in 50% of patients with primary myelofibrosis, 29% with polycythemia vera, and 8% to 10% with essential thrombocythemia. The relationship between the presence of such chromosomal abnormalities and the JAK2V617 allele burden, and the role that each of these genetic events play in the origins and progression of the myeloproliferative neoplasms (MPNs), remain unclear. Materials and Methods: Individual hematopoietic colonies were assayed in vitro from the CD34+ cells of six JAK2V617F-positive MPN patients with marker chromosomal abnormalities. Colonies were simultaneously analyzed for JAK2 genotype and chromosomal abnormalities. Results: Among the 248 colonies assayed from cultures containing 500 CD34+ cells, chromosomal abnormalities were detected in 5% of colonies with wild-type JAK2, 32% of JAK2V617F heterozygous colonies and 56% of JAK2V617F homozygous colonies. Overall, 92% of chromosomally abnormal colonies were also JAK2V617F homozygous. Although 54 colonies contained wild-type JAK2 exclusively, 4 of these colonies were characterized by chromosomal abnormalities. Conclusion: This study indicates that MPN hematopoietic progenitor cells do not necessarily always acquire genetic events in the same sequence. (Chromosomally abnormal progenitor cells are closely associated with JAK2V617F homozygosity; p = 0.0001.). Chromosomal abnormalities such as +8, +9 can occasionally precede acquisition of JAK2V617F. These findings support the existence of earlier genetic events that precede JAK2V617F or cytogenetic abnormalities in MPN hematopoietic progenitor cells.

UR - http://www.scopus.com/inward/record.url?scp=70249085509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70249085509&partnerID=8YFLogxK

U2 - 10.1016/j.exphem.2009.07.003

DO - 10.1016/j.exphem.2009.07.003

M3 - Article

C2 - 19615425

AN - SCOPUS:70249085509

VL - 37

SP - 1194

EP - 1200

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 10

ER -